trending Market Intelligence /marketintelligence/en/news-insights/trending/3gCrQEJWEYEvtYsxqL7auw2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Cardiol Therapeutics raises C$15.1M in IPO


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Cardiol Therapeutics raises C$15.1M in IPO

Cardiol Therapeutics Inc. has raised about C$15.1 million in gross proceeds from its IPO on the Toronto Stock Exchange.

The Oakville, Ontario-based biotechnology issued 3 million units for C$5 apiece in its IPO. Each unit in the offering comprised one common share and a two-year warrant to purchase a common share.

The company also issued an additional 374,544 warrants to underwriters who partially exercised their overallotment option. Warrants issued in the IPO can be exercised for one common share at C$6.50.

Cardiol's shares started trading on the Toronto Stock Exchange on Dec. 20 under the symbol CRDL.

David Elsley, president and CEO of Cardiol, said the funding raised will be used to commercialize the company's pharmaceutically manufactured ultra-pure cannabidiol products in the market for medical cannabinoids.

The IPO was made via a syndicate of underwriters led by AltaCorp Capital Inc. and including Mackie Research Capital Corp., Raymond James Ltd., Echelon Wealth Partners Inc. and Paradigm Capital Inc.